United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more
United Pharm (033270) - Net Assets
Latest net assets as of September 2025: ₩421.86 Billion KRW
Based on the latest financial reports, United Pharm (033270) has net assets worth ₩421.86 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩485.91 Billion) and total liabilities (₩64.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩421.86 Billion |
| % of Total Assets | 86.82% |
| Annual Growth Rate | 10.34% |
| 5-Year Change | 46.7% |
| 10-Year Change | 151.0% |
| Growth Volatility | 3.29 |
United Pharm - Net Assets Trend (2011–2024)
This chart illustrates how United Pharm's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for United Pharm (2011–2024)
The table below shows the annual net assets of United Pharm from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩406.21 Billion | +7.27% |
| 2023-12-31 | ₩378.68 Billion | +12.08% |
| 2022-12-31 | ₩337.86 Billion | +12.35% |
| 2021-12-31 | ₩300.71 Billion | +8.60% |
| 2020-12-31 | ₩276.89 Billion | +8.54% |
| 2019-12-31 | ₩255.10 Billion | +11.65% |
| 2018-12-31 | ₩228.48 Billion | +13.29% |
| 2017-12-31 | ₩201.68 Billion | +13.70% |
| 2016-12-31 | ₩177.39 Billion | +9.61% |
| 2014-12-31 | ₩161.83 Billion | +14.42% |
| 2013-12-31 | ₩141.44 Billion | +5.96% |
| 2012-12-31 | ₩133.48 Billion | +18.08% |
| 2011-12-31 | ₩113.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to United Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 327.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩401.37 Billion | 98.81% |
| Other Components | ₩4.83 Billion | 1.19% |
| Total Equity | ₩406.21 Billion | 100.00% |
United Pharm Competitors by Market Cap
The table below lists competitors of United Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
West Coast Paper Mills Limited
NSE:WSTCSTPAPR
|
$125.35 Million |
|
DOHOME
BK:DOHOME-R
|
$125.36 Million |
|
StealthGas Inc
NASDAQ:GASS
|
$125.36 Million |
|
Qingdao Richen Food Co Ltd
SHG:603755
|
$125.40 Million |
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
$125.33 Million |
|
Nantong Xingqiu Graphite Co. Ltd. A
SHG:688633
|
$125.29 Million |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
$125.26 Million |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
$125.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in United Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 378,681,044,240 to 406,207,015,450, a change of 27,525,971,210 (7.3%).
- Net income of 32,452,988,020 contributed positively to equity growth.
- Dividend payments of 6,141,352,980 reduced retained earnings.
- New share issuances of 1,345,777,400 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩32.45 Billion | +7.99% |
| Dividends Paid | ₩6.14 Billion | -1.51% |
| Share Issuances | ₩1.35 Billion | +0.33% |
| Other Changes | ₩-131.44 Million | -0.03% |
| Total Change | ₩- | 7.27% |
Book Value vs Market Value Analysis
This analysis compares United Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.47x to 0.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩13621.84 | ₩20050.00 | x |
| 2018-12-31 | ₩15431.99 | ₩20050.00 | x |
| 2019-12-31 | ₩17201.26 | ₩20050.00 | x |
| 2020-12-31 | ₩18654.34 | ₩20050.00 | x |
| 2021-12-31 | ₩20258.97 | ₩20050.00 | x |
| 2022-12-31 | ₩22970.86 | ₩20050.00 | x |
| 2023-12-31 | ₩25897.56 | ₩20050.00 | x |
| 2024-12-31 | ₩27611.96 | ₩20050.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently United Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.24%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.17x
- Recent ROE (7.99%) is below the historical average (11.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 17.88% | 13.89% | 0.86x | 1.50x | ₩8.90 Billion |
| 2012 | 12.27% | 12.15% | 0.72x | 1.41x | ₩3.03 Billion |
| 2013 | 8.63% | 8.92% | 0.71x | 1.37x | ₩-1.93 Billion |
| 2014 | 11.35% | 11.84% | 0.71x | 1.34x | ₩2.19 Billion |
| 2016 | 11.00% | 11.03% | 0.76x | 1.32x | ₩1.78 Billion |
| 2017 | 13.82% | 14.14% | 0.74x | 1.32x | ₩7.70 Billion |
| 2018 | 13.86% | 14.94% | 0.70x | 1.32x | ₩8.82 Billion |
| 2019 | 12.12% | 13.97% | 0.67x | 1.30x | ₩5.41 Billion |
| 2020 | 9.61% | 12.32% | 0.61x | 1.28x | ₩-1.08 Billion |
| 2021 | 9.53% | 12.96% | 0.58x | 1.26x | ₩-1.42 Billion |
| 2022 | 13.40% | 17.25% | 0.63x | 1.24x | ₩11.49 Billion |
| 2023 | 12.74% | 17.30% | 0.59x | 1.24x | ₩10.39 Billion |
| 2024 | 7.99% | 11.24% | 0.61x | 1.17x | ₩-8.17 Billion |
Industry Comparison
This section compares United Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| United Pharm (033270) | ₩421.86 Billion | 17.88% | 0.15x | $125.34 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |